Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
they will try---- its not like a run on the stock.............
Shorters are bastard earning nothing in shorting this kind of stock!!
what a f disaster,God bless and good luck
Very bad… 99% holdings in hand of public!!!
Confuscios say ''buy low---- sell high''
Over 30 years company…Only 11 employees and very few financial institutional investors …very bad…
to boot klauss is making near 750k a yr for cratering aezs pps,sma aezs and klauss,God bless all
what a f disaster this has turned out to be,we all make mistakes and this is 1 for both of us,f aholes take forever to get things done,novo backed out of deal.this could easily go down below a buck again,sorry but we both fd up with this pos,tax rt off is all,and we all make mistakes sometimes,should have looked at past performance also,since its inception all it has done is go down,unless macrilen can be used for other things besides a test they got 0,sorry for our losses,God bless and good luck
No more oral COVID pill… a spam..
this stock seems to ALWAYS come back in SPADES
a good friend of mine had 2 of those Citroens... a engineered marvel
1950's were the days of the Jackal's
Instead of giving updates, company chooses to publish those old information which already published .. it is not alert at all! It just so amazing a company keeps on publishing old information not bothering how public would expect.
on the list ???
Listing of Company Delinquent Filings Update
10/04/2022
You are subscribed to receive Listings of Company Delinquent Filings from the Securities and Exchange Commission.
This information has recently been updated and is now available.
https://www.sec.gov/divisions/enforce/delinquent/delinqindex.htm
BOND JAMES couldnt save it,,, but James BLOND will ,,,,,with secret tricks
watch
On November 16, 2020, the Company announced that it had entered into the Novo Amendment related to the development and commercialization of macimorelin. Novo is currently marketing macimorelin in the U.S. under the trade name Macrilen™ for the diagnosis of AGHD. Aeterna, in collaboration with Novo, is currently developing the expanded use of macimorelin for the diagnosis of CGHD, an area of significant unmet medical need.
On December 7, 2020, the Company entered into an exclusive licensing agreement with Consilient Health Limited (“CH” or “Consilient”) for the commercialization of macimorelin in the European Economic Area and the United Kingdom. In December 2021, the Department of Health and Social Care in the United Kingdom approved a list price which triggered a $226 (€0.2 million) pricing milestone payment from CH to the Company. In Germany, a list price was approved on June 15, 2022 which triggered a second $226 (€0.2 million) pricing milestone payment from CH to the Company. We shipped initial batches of macimorelin (Ghryvelin®) to Consilient in the first quarter of 2022. Consilient launched the product in the United Kingdom, Sweden and Denmark in May 2022 and launches in Germany and Finland are scheduled for July 2022.
We entered into license and supply agreements with NK Meditech Ltd. (“NK”), a subsidiary of PharmBio Korea, effective November 30, 2021, and a distribution and commercialization agreement with ER Kim Pharmaceuticals Bulgaria Food (“ER-Kim”), effective February 1, 2022. The agreements with NK are related to the development and commercialization of macimorelin for the diagnosis of AGHD and CGHD in the Republic of Korea, while the agreement with ER-Kim is related to the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries.
On April 19, 2022, we announced that European Patent Office had issued a patent providing intellectual property protection of macimorelin in 27 countries within the European Union as well as additional European non-EU countries, such as the UK and Turkey, for macimorelin (Ghryvelin®; Macrilen™) for use to diagnose GHD in adults.
Follow the money folks!!!
#ELGORDODAMUS
$AEZS
Could this become a $100 ticker
In the next 6-18 months
It’s been on my radar for over a year
Let see how it plays out.
#ELGORDODAMUS
$AEZS
yah, when you got a billion shares--there are lots of reverse splits to be done ---
Further adjourning shareholders meeting. Klaus, don’t waste your time. It’s time to consider AEZS to buy back some share from the market. Or else AEZS is facing delisting..
Just a pump & dump.. really crab!
patrick i have to be honest,i sold because i needed the money to fix driveway,took a big hit but didnt have a choice really,God bless and good luck,sorry we were wrong about this 1 ,i dont know whats going to happen with this,if catalysts come to fruition it will jump back but at the rate they are going it could take a while and rs are almost always bad,God bless and good luck bro
The share consolidation did not get shareholders approval… going to be delisted or going to pink… AEZS has sufficient cash to buy back 100 million shares and still leaving plenty amount for R&D. Buy back shares also show management is confident on its current candidates! AEZS is very risky facing delisted! What have you voted on this?
no way to test kids for ghd,no way,after approval it will help a lot,again no way to test kids for ghd,0 competition,what sucks is the delay because of putins war and the other catalysts takng forever like the covid pill,no urgency,sh feel it,check out tsoi,cant recommend per rules but check it out
Shorters keep shorting this stock in view of RS. Management is bad and this stock is crab!
Pedi test is just a test, not a drug.., not much value, right?!
sorry patrickt,the pedi test final trial being delayed has killed us along with all the other catalysts taking forever,God bless bro
Recent news on NMOSD is useless.. target patient population is talking about 10000-15000 patients only!
Recent news on proved concept on OMOSD is only for 10000-15000 patients. Candidates for just so small population are of little market value however it said unmet needs. And COVID is now gone! Story on oral COVID pill also of little value! Very bad management indeed!
it wont,just that rs are rarely good for sh,if they back it up with substantial news we would be ok,sooner or later the news will come,i just hope it doesnt take forever,like the pedi test,we need it approved and selling,God bless bro
If this goes pink or delisted, I would be in big trouble…
i wish i knew bro,just remember i was down 90% once in his and ended up making money in the end,i am down 10k recently with the huge drop though,God bless and good luck bro
When will AEZS has FDA news on candidates?
Damn these shortest! And crab management!
sorry patrick,ive felt the sting too but i would hold till some of these catalysts come to fruition especially the ones for unmet needs,i wouldnt take the loss but its been a big disssapointment i agree,taking forever with everything,sorry bud,God bless and good luck
Horrible stock..horrible management..invalid phone no published in FB..
It is all pk!
rt now,yes,God bless
Maybe AEZS was a real company but not already. It is terrible a real company with its company phone number being INVALID!
patrick its a real company,they have a licensing deal with novo and multiple things in pipeline,its been a shit show for sure especially pedi being delayed because of putins war and hate idea of rs,remember my story of being down 90% once in aezs and ended up making money,just hold,dont take a big loss as this will recover at some point when catalysts start coming in,i know it sucks but hold bro,a yr from now it will be much higher imo or if u take the loss buy back in in another account so u would be starting fresh with an average in low 20s but it must b a different account,i sold all in my individual account and bought back in my ira,again way too many catalysts coming longterm,hold or if u want to take the loss take it and buy back in another account,sorry for our losses,God bless bro and good luck 2
A company with invalid phone number, and investors relation contact no just voice recording… no idea whether this is a real company or not.. very terrible.
agreed,terrible,who knew it was going to take forever for these catalysts to come thru,f joffs,God bless and good luck bro,sorry for our losses
The FB information for AEZS phone no +498334758247 is an invalid phone!! Really a scam!! https://www.facebook.com/aezsinc/?ref=page_internal
How many shares owned by financial institutions? Is it just 2%?? If yes, majority is public shareholders - owning 120 million shares ..? RS is damaging public shareholders..
Wtf….not able to sell in the market now.. don’t know why..
Followers
|
301
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
18784
|
Created
|
05/09/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |